<i>Best Practice No 179</i>

Ellis, Ian O.; Humphreys, S.; Michell, Michael; Pinder, Sarah; Wells, Clive; Zakhour, H. D.

doi:10.1136/jcp.2003.010983

Cited by 105 publications

(65 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The strength of the VABB systems lies, however, in their high predictive value for the absence of malignancy (VPN). In this study and in our previous wider experience [1] in no case of VABB microhistological findings classified as benign did we later find the onset of a malignant lesion in the VABB sampling site, in agreement with other studies [8,13,19,20].…”

Section: Discussionsupporting

confidence: 81%

See 1 more Smart Citation

Mammotome® and EnCor®: comparison of two systems for stereotactic vacuum-assisted core biopsy in the characterisation of suspicious mammographic microcalcifications alone

et al. 2014

View full text Add to dashboard Cite

the lesions. The two systems did not differ statistically for correlation with the final histology (S1 k = 0.94 ± 0.06; S2 k = 0.92 ± 0.08) and underestimation of B3 lesions or in situ (S1 4.5 %; S2 4.3 %). Sensitivity, specificity, PPV, NPV, diagnostic accuracy of S1 and S2 were also not statistically different. The systems differed only in sampling time (S1 80; S2 63 s), but not in total procedure time. Conclusions Our study confirms the effectiveness of VABB in the assessment of microcalcifications and highlights the lack of significant differences between the two systems in terms of diagnostic performance.

show abstract

Section: Discussionsupporting

confidence: 81%

“…According to the European Guidelines, the microhistological examinations of the samples obtained by VABB were classified into five categories: B1 = normal, B2 = benign, B3 = lesion of uncertain significance, B4 = suspected malignancy, B5 = malignant [8].…”

Section: Interpretation Of Resultsmentioning

confidence: 99%

Mammotome® and EnCor®: comparison of two systems for stereotactic vacuum-assisted core biopsy in the characterisation of suspicious mammographic microcalcifications alone

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The biopsies were reviewed by two independent pathologists. The results of the biopsies were classified as B1 to B5-lesions, according to the UK B-coding guidelines (8). All patients with a B3-lesion on NCB were discussed at a multidisciplinary meeting, attended by breast radiologists, pathologists and gynecologists, and a decision was made regarding further treatment.…”

Section: Patientsmentioning

confidence: 99%

B3-lesions of the breast and cancer risk - an analysis of mammography screening patients

Hoffmann

Stamatis

Bittner

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The use of mammography screening, followed by needle core biopsy (NCB), is associated with an increasing amount of invasive procedures. A considerable amount of specimens must be classified as lesions with uncertain malignant potential (B3-lesion). In these cases, an open biopsy is indicated for further diagnosis. We evaluated patients with B3-lesions to determine the risk of malignancy corresponding to the histopathological NCB results and the type of radiological lesion identified. A total of 95 patients participating in the German mammography screening program with a B3-lesion following NCB (104 B3-lesions in total) were included in our analysis. We analyzed the correlation between the initial histopathological findings from the NCB specimen and cancer risk. We further analyzed the correlations of malignant results with the type of mammographic lesion. In 23 cases (22%), histopathological examination following excision revealed a malignant lesion, including invasive and in situ carcinoma. The positive predictive value of the subgroups of B3-lesions ranged between 0.11 and 0.31; the B3-lesion associated with the highest cancer risk was the atypical ductal hyperplasia; however, no significant difference was observed between the B3-lesion subgroups (P=0.309) regarding the risk of malignancy. Comparing the different types of mammographic findings, such as radiological mass or microcalcifications, there was no significant difference in the risk for malignancy (P=0.379). The different types of B3-lesions did not exhibit differences in the risk for malignancy, and the morphological type of mammographic lesion does not appear to be correlated with cancer risk; therefore, our results underline the need for open biopsy in patients with B3-lesions following NCB.

show abstract

“…Traditionally, these lesions have been managed by surgical excision [85,86], whereas LN has mostly been managed non-operatively. Surgery has also become the standard treatment for ADH diagnosed on CNB, since 25% of cases are associated with malignancy [89].…”

Section: Surgical Managementmentioning

confidence: 99%

Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast–A review

Hussain

Cunnick

2011

European Journal of Surgical Oncology

View full text Add to dashboard Cite

To cite this version:M. Hussain, G.H. Cunnick. Management of lobular carcinoma in situ and atypical lobular hyperplasia of the breast -A review. EJSO -European Journal of Surgical Oncology, WB Saunders, 2011, 37 (4) This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.We are submitting the article "Management of Lobular Neoplasia in Situ and Atypical Lobular Hyperplasia -A Review" to your auspicious journal with your kind permission. We have made an effort in an attempt to address the management controversies surrounding lobular Neoplasia on reviewing the currently available literature and have made some management recommendations based on the evidence available.We have also declared no funding and no conflict of interest on the authors' form.Whilst, I (Mubashar Hussain) remain the first author for the paper, Mr G Cunnick could be kindly contacted for correspondence. malignancy. 29% of the unspecified LNs were upgraded to malignancy. The higher incidence of malignancy within excision specimens for LCIS and PLCIS compared to ALH was significant (P<0.04, <0.003 respectively). Conclusion:There is a significant under-estimation of malignancy in patients diagnosed with breast LN on CNB. 27% cases of CNB-diagnosed LN were found to contain malignancy following surgical excision. All patients diagnosed with LN on CNB should be considered for surgical excision biopsy.

show abstract

Best Practice No 179

Cited by 105 publications

References 9 publications

Mammotome® and EnCor®: comparison of two systems for stereotactic vacuum-assisted core biopsy in the characterisation of suspicious mammographic microcalcifications alone

Mammotome® and EnCor®: comparison of two systems for stereotactic vacuum-assisted core biopsy in the characterisation of suspicious mammographic microcalcifications alone

B3-lesions of the breast and cancer risk - an analysis of mammography screening patients

Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast–A review

Contact Info

Product

Resources

About